ÂÜÀòÂÒÂ×

Takaaki Ishii, a molecular biologist by training, joined Taiho Ventures in 2019. He has acquired over 11 years of oncology expertise in early stage clinical development, product portfolio strategies as well as scientific evaluations for in-house and potential partnering programs in a wide range of cancer types. His representative contribution to Taiho Pharmaceutical includes in-licensing AB928 (A2aR/A2bR Dual Antagonist) from Arcus Biosciences as well as both medical and Medical Science Liaison activities for nab-paclitaxel (ABRAXANE®) and pembrolizumab (KEYTRUDA®) in Japan.